Mitogen-Activated Protein Kinase Phosphorylation of Splicing Factor 45 (SPF45) Regulates SPF45 Alternative Splicing Site Utilization, Proliferation, and Cell Adhesion

Molecular and Cellular Biology

Volumn 32, Issue 14, 2012, Pages 2880-2893

  Al Ayoubi, Adnan M ^a   Zheng, Hui ^a   Liu, Yuying ^a   Bai, Tao ^a   Eblen, Scott T ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANISOMYCIN; BINDING PROTEIN; FIBRONECTIN; HYDROGEN PEROXIDE; MEMBRANE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDES AND PROTEINS; PROTEIN P38 ALPHA; SPLICING FACTOR 45; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL ADHESION; CELL PROLIFERATION; ENZYME ACTIVATION; EXON; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOPRECIPITATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA SPLICING; ULTRAVIOLET RADIATION;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD95; BASE SEQUENCE; CELL ADHESION; CELL LINE; CELL PROLIFERATION; DNA PRIMERS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBRONECTINS; HELA CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 14; MITOGEN-ACTIVATED PROTEIN KINASE 8; PHOSPHORYLATION; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; RNA PRECURSORS; RNA SPLICE SITES; RNA-BINDING PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84863992155     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06327-11     Document Type: Article

References (66)

1. Al-Ayoubi A, Tarcsafalvi A, Zheng H, Sakati W, Eblen ST. 2008. ERK activation and nuclear signaling induced by the loss of cell/matrix adhesion stimulates anchorage-independent growth of ovarian cancer cells. J. Cell Biochem. 105:875-884.
2. Aravind L, Koonin EV. 1999. G-patch: a new conserved domain in eukaryotic RNA-processing proteins and type D retroviral polyproteins. Trends Biochem. Sci. 24:342-344.
3. Benz CC, et al. 1997. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15:1513-1525.
4. Berchuck A, et al. 1990. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:4087-4091.
5. Blaustein M, Pelisch F, Srebrow A. 2007. Signals, pathways and splicing regulation. Int. J. Biochem. Cell Biol. 39:2031-2048.
6. Blencowe BJ. 2006. Alternative splicing: new insights from global analyses. Cell 126:37-47.
7. Boyle WJ, van der Geer P, Hunter T. 1991. Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thinlayer cellulose plates. Methods Enzymol. 201:110-149.
8. Caceres JF, Misteli T, Screaton GR, Spector DL, Krainer AR. 1997. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J. Cell Biol. 138:225-238.
9. Carlson SM, et al. Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3. Sci. Signal. 4:rs11. doi: 10.1126/scisignal.2002010.
10. Casey RC, et al. 2001. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am. J. Pathol. 159: 2071-2080.
11. Chang CH, et al. 1997. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 14:1617-1622.
12. Chaouki AS, Salz HK. 2006. Drosophila SPF45: a bifunctional protein with roles in both splicing and DNA repair. PLoS Genet. 2:e178. doi: 10.1371/journal.pgen.0020178.
13. Chauhan AK, Moretti FA, Iaconcig A, Baralle FE, Muro AF. 2005. Impaired motor coordination in mice lacking the EDA exon of the fibronectin gene. Behav. Brain Res. 161:31-38.
14. Chen RH, Tung R, Abate C, Blenis J. 1993. Cytoplasmic to nuclear signal transduction by mitogen-activated protein kinase and 90 kDa ribosomal S6 kinase. Biochem. Soc. Trans. 21:895-900.
15. Cheng J, et al. 1994. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762.
16. Corsini L, et al. 2007. U2AF-homology motif interactions are required for alternative splicing regulation by SPF45. Nat. Struct. Mol. Biol. 14:620-629.
17. Cramer P, et al. 1999. Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. Mol. Cell 4:251-258.
18. Desoize B, Jardillier J. 2000. Multicellular resistance: a paradigm for clinical resistance? Crit. Rev. Oncol. Hematol. 36:193-207.
19. Eblen ST, Catling AD, Assanah MC, Weber MJ. 2001. Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2. Mol. Cell. Biol. 21:249-259.
20. Eblen ST, et al. 2003. Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs. J. Biol. Chem. 278:14926-14935.
21. Eblen ST, Kumar NV, Weber MJ. 2007. Using genetically engineered kinases to screen for novel protein kinase substrates: generation of [{gamma}-32P]ATP analog from ADP analog. CSH Protoc. 2007:pdb.prot4637. doi: 10.1101/pdb.prot4637.
22. Eblen ST, Kumar NV, Weber MJ. 2007. Using genetically engineered kinases to screen for novel protein kinase substrates: phosphorylation of kinase-associated substrates. CSH Protoc. 2007:pdb.prot4638. doi: 10.1101/pdb.prot4638.
23. Eblen ST, Kumar NV, Weber MJ. 2007. Using genetically engineered kinases to screen for novel protein kinase substrates: phosphorylation of substrates in cell lysates with exogenous kinase. CSH Protoc. 2007: pdb.prot4639. doi:10.1101/pdb.prot4639.
24. Eblen ST, et al. 2004. Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol. Cell. Biol. 24:2308-2317.
25. Fernandez-Medarde A, Santos E. 2011. Ras in cancer and developmental diseases. Genes Cancer 2:344-358.
26. Frenal K, et al. 2006. Structural and functional characterization of the TgDRE multidomain protein, a DNA repair enzyme from Toxoplasma gondii. Biochemistry 45:4867-4874.
27. Hanamura A, Caceres JF, Mayeda A, Franza BR, Jr, Krainer AR. 1998. Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA 4:430-444.
28. Hastings ML, Krainer AR. 2001. Functions of SR proteins in the U12-dependent AT-AC pre-mRNA splicing pathway. RNA 7:471-482.
29. Hastings ML, Krainer AR. 2001. Pre-mRNA splicing in the new millennium. Curr. Opin. Cell Biol. 13:302-309.
30. Izquierdo JM, et al. 2005. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol. Cell 19:475-484.
31. Khokhlatchev A, et al. 1997. Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases. J. Biol. Chem. 272:11057-11062.
32. Kumar NV, Eblen ST, Weber MJ. 2004. Identifying specific kinase substrates through engineered kinases and ATP analogs. Methods 32:389-397.
33. Lallena MJ, Chalmers KJ, Llamazares S, Lamond AI, Valcarcel J. 2002. Splicing regulation at the second catalytic step by Sex-lethal involves 3= splice site recognition by SPF45. Cell 109:285-296.
34. Lenormand P, et al. 1993. Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J. Cell Biol. 122:1079-1088.
35. Lewis TS, et al. 2000. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol. Cell 6:1343-1354.
36. Lewis TS, Shapiro PS, Ahn NG. 1998. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74:49-139.
37. Manley JL, Tacke R. 1996. SR proteins and splicing control. Genes Dev. 10:1569-1579.
38. Matlin AJ, Clark F, Smith CW. 2005. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 6:386-398.
39. Matter N, Herrlich P, Konig H. 2002. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420:691-695.
40. Maurer G, Tarkowski B, Baccarini M. 2011. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 30:3477-3488.
41. Mayeda A, Munroe SH, Caceres JF, Krainer AR. 1994. Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 13:5483-5495.
42. Modrek B, Resch A, Grasso C, Lee C. 2001. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 29:2850-2859.
43. Mortz E, Krogh TN, Vorum H, Gorg A. 2001. Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics 1:1359-1363.
44. Muro AF, et al. 2008. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177:638-645.
45. Neubauer G, et al. 1998. Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex. Nat. Genet. 20:46-50.
46. Olsen JV, et al. 2006. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127:635-648.
47. Pelisch F, Blaustein M, Kornblihtt AR, Srebrow A. 2005. Cross-talk between signaling pathways regulates alternative splicing: a novel role for JNK. J. Biol. Chem. 280:25461-25469.
48. Perry WL, 3rd, et al. 2005. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed- a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 65:6593-6600.
49. Prasad J, Colwill K, Pawson T, Manley JL. 1999. The protein kinase Clk/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing. Mol. Cell. Biol. 19:6991-7000.
50. Sampath J, et al. 2003. Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am. J. Pathol. 163:1781-1790.
51. Schaeffer HJ, Weber MJ. 1999. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 19:2435-2444.
52. Scott GK, et al. 2000. Ets regulation of the erbB2 promoter. Oncogene 19:6490-6502.
53. Shah K, Liu Y, Deirmengian C, Shokat KM. 1997. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc. Natl. Acad. Sci. U. S. A. 94:3565-3570.
54. Shepherd TG, Kockeritz L, Szrajber MR, Muller WJ, Hassell JA. 2001. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr. Biol. 11:1739-1748.
55. Silverman EJ, et al. 2004. Interaction between a G-patch protein and a spliceosomal DEXD/H-box ATPase that is critical for splicing. Mol. Cell. Biol. 24:10101-10110.
56. Sodek KL, Ringuette MJ, Brown TJ. 2009. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int. J. Cancer 124:2060-2070.
57. Stamm S. 2008. Regulation of alternative splicing by reversible protein phosphorylation. J. Biol. Chem. 283:1223-1227.
58. Svec M, Bauerova H, Pichova I, Konvalinka J, Strisovsky K. 2004. Proteinases of betaretroviruses bind single-stranded nucleic acids through a novel interaction module, the G-patch. FEBS Lett. 576:271-276.
59. Tanoue T, Adachi M, Moriguchi T, Nishida E. 2000. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2:110-116.
60. van der Houven van Oordt W, et al. 2000. The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J. Cell Biol. 149:307-316.
61. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA. 1987. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1:423-430.
62. Weg-Remers S, Ponta H, Herrlich P, Konig H. 2001. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 20:4194-4203.
63. White ES, Baralle FE, Muro AF. 2008. New insights into form and function of fibronectin splice variants. J. Pathol. 216:1-14.
64. White ES, et al. 2010. Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Exp. Cell Res. 316: 2644-2653.
65. Will CL, Luhrmann R. 2001. Spliceosomal UsnRNP biogenesis, structure and function. Curr. Opin. Cell Biol. 13:290-301.
66. Xing Y, Lee C. 2007. Relating alternative splicing to proteome complexity and genome evolution. Adv. Exp. Med. Biol. 623:36-49.